Table 3.
Demographic Characteristics of the Study Patients
| Characteristic | Misoprostol (n=237) | Rebamipide (n=242) | Total (n=479) | p-value |
|---|---|---|---|---|
| Age, yr | 55.8±12.2 | 55.8±12.2 | 55.8±12.2 | 0.9640* |
| Sex | ||||
| Male | 44 (18.6) | 42 (17.4) | 86 (18.0) | 0.8119† |
| Female | 193 (81.4) | 200 (82.6) | 393 (82.1) | |
| Smokers‡ | 36 (15.2) | 42 (17.4) | 78 (16.3) | 0.5383† |
| Risk factors | ||||
| Peptic ulcer history | 27 (11.4) | 21 (8.7) | 48 (10.0) | 0.3627† |
| ≥60 Years of age | 124 (52.3) | 118 (48.8) | 242 (50.5) | 0.4652† |
| Concomitant use of systemic corticosteroids | 132 (55.7) | 153 (63.2) | 285 (59.5) | 0.0951† |
| Concomitant disease | ||||
| Rheumatoid arthritis | 149 (62.9) | 160 (66.1) | 309 (64.5) | 0.5040† |
| Osteoarthritis | 79 (33.3) | 79 (32.6) | 158 (33.0) | 0.9226† |
| Ankylosing spondylitis | 14 (5.9) | 5 (2.1) | 19 (4.0) | 0.0358† |
| Other§ | 43 (18.1) | 40 (16.5) | 83 (17.3) | 0.7174† |
| Modified Lanza score (from the screening endoscopy) | ||||
| Grade 0 | 124 (52.3) | 132 (54.6) | 256 (53.4) | 0.1636† |
| Grade 1 | 48 (20.3) | 55 (22.7) | 103 (21.5) | |
| Grade 2 | 40 (16.9) | 24 (9.9) | 64 (13.4) | |
| Grade 3 | 25 (10.6) | 30 (12.4) | 55 (11.5) | |
| Grade 4 | 0 | 0 | 0 | |
| Grade 5 | 0 | 1 (0.4)|| | 1 (0.2) |
Data are presented as mean±SD or number (%).
*
Two-sample t-test;
†
Fisher exact test;
‡
Smokers were defined as individuals who reported any tobacco use;
§
Osteoporosis, systemic lupus erythematous, and spinal stenosis;
||
Major deviation from the inclusion criteria.